Table 23:
Scenario 5: OHIP+ Volume, Accounting for Uptake of Multi-gene Pharmacogenomic Testing in Ontario, Years 1 to 5
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Eligible (with major depression): aged 15 to 24 y Uptake rate Assessed with a multi-gene pharmacogenomic test: aged 15 to 24 ya |
28,233 0.20 5,647 |
28,657 0.40 9,204 |
29,045 0.60 8,516 |
29,330 0.80 4,771 |
29,499 1.00 1,361 |
| Eligible (with major depression): aged ≥ 25 y Uptake rate Assessed with a multi-gene pharmacogenomic test: aged ≥ 25 ya |
155,314 0.01 1,553 |
157,854 0.02 3,126 |
160,218 0.03 4,666 |
162,461 0.04 6,125 |
164,608 0.05 7,457 |
| Total volume: pharmacogenomic testing (all age groups) | 7,200 | 12,330 | 13,182 | 10,896 | 8,818 |
a
Uptake rate applied to approximate total number remaining eligible for testing in the specific year: e.g., year 1 (aged 15–24): 28,233 × 0.20 = 5,647, or year 1 (aged ≥ 25): 155,314 × 0.01 = 1,553; year 2 (aged 15–24): (28,657 – 5,647) × 0.40 = 9,204 or year 2 (aged ≥ 25): (157,854 – 1,553) × 0.02 = 3,126; year 3 (aged 15—24): (29,045 – 5,647 – 9,204) × 0.60 = 8,516 or year 3 (aged ≥ 25): (160,218 – 1,553 – 3,126) × 0.03 = 4,666, etc. Those tested in prior years are subtracted from the population in the following years, as the cost of test is applied only once over a person's lifetime.99